Related Experiment Video
Updated: Aug 17, 2026

Rapid In Situ Hybridization using Oligonucleotide Probes on Paraformaldehyde-prefixed Brain of Rats with Serotonin Syndrome
Published on: September 23, 2015
Regional reductions in serotonin 1A receptor binding in juvenile myoclonic epilepsy
Anna Meschaks1, Per Lindstrom, Christer Halldin
1Division of Neurology, NEUROTEC, Stockholm, Sweden.
Background:
Juvenile myoclonic epilepsy (JME) is classified as primarily generalized epilepsy and as such is assumed to lack an anatomic substrate. Although neurochemical abnormalities are probable, few studies have investigated whether they exist in JME. Animal data and the high incidence of myoclonic seizures in serotonin-intoxicated patients suggest that the serotonin system may be disturbed in JME.
Objective:
To test the hypothesis that JME is associated with a disturbed serotonin system and that this disturbance could be reflected in altered serotonin 1A receptor binding.
Design:
The serotonin 1A receptor binding potential (BP) was measured with positron emission tomography and serotonin 1A receptor antagonist carbonyl-carbon 11-WAY-100635. The BP was calculated using a reference tissue model in several limbic and neocortical regions and the raphe nuclei.
Setting:
Epilepsy clinics of the Karolinska University Hospital, Stockholm, Sweden.
Patients:
Eleven patients with JME and 11 controls were studied.
Main Outcome Measure:
Serotonin 1A receptor BP calculated in a set of volumes of interest.
Results:
The patients with JME showed a reduced BP in the dorsolateral prefrontal cortex, raphe nuclei, and hippocampus.
Conclusions:
The observed reductions in serotonin 1A receptor BP suggest that the serotonin system is affected in JME. Although the data give no definitive information about underlying mechanisms, they provide a strong argument for the view that not all brain regions are homogeneously involved in this condition, further questioning the current classification of primarily generalized epilepsy.
More Related Videos
Related Concept Videos
Drugs Affecting Neurotransmitter Release or Uptake
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
G-protein Coupled Receptors
Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
Antiepileptic Drugs: Glutamate Antagonists

